Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer
Authors
Keywords
-
Journal
International Journal of Clinical Pharmacy
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-11
DOI
10.1007/s11096-020-01076-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the 1st-line treatment of squamous NSCLC in the U.S.
- (2019) Ralph P Insinga et al. CURRENT MEDICAL RESEARCH AND OPINION
- First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma
- (2019) XiaoMin Wan et al. JAMA Oncology
- Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)
- (2019) Umang Ondhia et al. JOURNAL OF MEDICAL ECONOMICS
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
- (2019) Howard West et al. LANCET ONCOLOGY
- Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer
- (2019) Kexun Zhou et al. LUNG CANCER
- First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis
- (2019) XiaoMin Wan et al. CANCER
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: a cost-effectiveness analysis from the UK health care perspective
- (2018) Xiaohan Hu et al. LUNG CANCER
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer
- (2018) Pedro N. Aguiar et al. JAMA Oncology
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016
- (2018) et al. JAMA Oncology
- Cost‐Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR‐Mutation‐Positive Non‐Small Cell Lung Cancer
- (2018) Bin Wu et al. ONCOLOGIST
- Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US
- (2018) Ralph P. Insinga et al. JOURNAL OF MEDICAL ECONOMICS
- NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018
- (2018) Gregory P. Kalemkerian et al. Journal of the National Comprehensive Cancer Network
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non–Small Cell Lung Cancer in the Context of the US Health Care System
- (2018) Steven D. Criss et al. JAMA Oncology
- Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy
- (2017) Lais Osmani et al. SEMINARS IN CANCER BIOLOGY
- Health state utilities in non-small cell lung cancer: An international study
- (2016) Beenish Nafees et al. Asia-Pacific Journal of Clinical Oncology
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
- (2016) Min Huang et al. JOURNAL OF MEDICAL ECONOMICS
- Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial
- (2015) Domenico Galetta et al. Clinical Lung Cancer
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2013) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
- (2012) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- Health state utilities for non small cell lung cancer
- (2008) Beenish Nafees et al. Health and Quality of Life Outcomes
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now